Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Janssen Introduces Business Units for Sales & Marketing
January 11, 2010
- Fulvestrant Applied for Postmenopausal Breast Cancer
January 11, 2010
- 5,032 Applicants for 16th Examination for MR Certification
January 11, 2010
- AFM to Manage Supply of All Drugs to Hospitals
January 11, 2010
- Tamiflu Approved for Prevention in Infants, Children
January 11, 2010
- Korosho to Reallocate Increased Medical Fees
January 11, 2010
- Kowa to Copromote Livalo with Lilly in the US
January 11, 2010
- Bup-4 Approved for Problems Associated with OAB
January 11, 2010
- Only 10% of Consumers Fail to Buy Class 1 OTC Drugs due to Absence of Pharmacists
January 11, 2010
- Ranbaxy to Market Olmesartan in 6 African Countries
January 11, 2010
- Pricing System Reform to Trigger Industry Reorganization
January 11, 2010
- Aricept's Medicoeconomic Benefits Demonstrated
January 11, 2010
- Bayer to Integrate Intendis in April
January 11, 2010
- Pfizer to Break Away from Dependence on Blockbusters: New President Umeda
January 11, 2010
- Female Doctors Tend to Stay Away from Surgery Dept.: Korosho
January 11, 2010
- Welfide Korea Renamed Mitsubishi Tanabe Pharma Korea
January 11, 2010
- FDA Advisory Committee Votes in Favor of Line Extension for Crestor
January 11, 2010
- Toho to Completely Acquire Asucome in February
January 11, 2010
- Coefficient for Generics Not to Be Introduced This April
January 11, 2010
- FPMAJ, JPMA Welcome New Premium as a Step toward New Pricing System
January 11, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…